Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Forrest

Showing results (81-90 of 177) with videos related to

Pageof 18
Sort By:
Antimicrobial Agents and Chemotherapy|May 16, 2018
Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control AlgorithmElizabeth A Lakota, Cornelia B Landersdorfer, Roger L Nation, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2007
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infectionPatrick F Smith, Abayomi Ogundele, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2014
Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studiesOlanrewaju O Okusanya, Sujata M Bhavnani, Jeffrey P Hammel, et al.
Journal of Managed Care Pharmacy : JMCP|September 19, 2007
Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacistsJennifer L Donovan, Walter S Schroeder, Maichi T Tran, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 28, 2011
Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia populationAnthony Jarkowski, Alan Forrest, Richard P Sweeney, et al.
International Journal of Antimicrobial Agents|March 31, 2021
Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomesThamer A Almangour, Estefany Garcia, Qi Zhou, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2003
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjectsRobert DiCenzo, Alan Forrest, Kathleen E Squires, et al.
The New Phytologist|December 21, 2018
Macroevolutionary dynamics of nectar spurs, a key evolutionary innovationMario Fernández-Mazuecos, José Luis Blanco-Pastor, Ana Juan, et al.
Clinical Pharmacology and Therapeutics|April 25, 2022
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical FactorsSpinel Karas, Ron H J Mathijssen, Ron H N van Schaik, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2007
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection modelPaul G Ambrose, Alan Forrest, William A Craig, et al.
Pageof 18

Showing results (81-90 of 177) with videos related to

Sort By:
Pageof 18
Antimicrobial Agents and Chemotherapy|May 16, 2018
Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control AlgorithmElizabeth A Lakota, Cornelia B Landersdorfer, Roger L Nation, et al.
Antimicrobial Agents and Chemotherapy|July 20, 2007
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infectionPatrick F Smith, Abayomi Ogundele, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2014
Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studiesOlanrewaju O Okusanya, Sujata M Bhavnani, Jeffrey P Hammel, et al.
Journal of Managed Care Pharmacy : JMCP|September 19, 2007
Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacistsJennifer L Donovan, Walter S Schroeder, Maichi T Tran, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 28, 2011
Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia populationAnthony Jarkowski, Alan Forrest, Richard P Sweeney, et al.
International Journal of Antimicrobial Agents|March 31, 2021
Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomesThamer A Almangour, Estefany Garcia, Qi Zhou, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2003
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjectsRobert DiCenzo, Alan Forrest, Kathleen E Squires, et al.
The New Phytologist|December 21, 2018
Macroevolutionary dynamics of nectar spurs, a key evolutionary innovationMario Fernández-Mazuecos, José Luis Blanco-Pastor, Ana Juan, et al.
Clinical Pharmacology and Therapeutics|April 25, 2022
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical FactorsSpinel Karas, Ron H J Mathijssen, Ron H N van Schaik, et al.
Antimicrobial Agents and Chemotherapy|September 19, 2007
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection modelPaul G Ambrose, Alan Forrest, William A Craig, et al.
Pageof 18